Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A tau protein expression inhibitor is a molecule or therapeutic agent designed to reduce the production or accumulation of tau protein within cells, particularly neurons. Tau is a microtubule-associated protein primarily found in the central nervous system, where it stabilizes microtubules and supports neuronal structure and function. Abnormal expression, hyperphosphorylation, or aggregation of tau is implicated in neurodegenerative diseases known as tauopathies, including Alzheimer's disease. Inhibiting tau expression aims to lower total cellular levels of both normal and pathological forms of tau, reduce formation of toxic aggregates that drive neurodegeneration, and potentially slow progression or modify the course of diseases like Alzheimer's.
Antisense oligonucleotides (bind to MAPT mRNA); small molecule transcriptional/translational blockers; peptide inhibitors targeting aggregation hotspots
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tau Protein Expression Inhibitor.